# In-patient COVID-19 Study of Intranasal Foralumab

> **NCT04983446** · PHASE2 · WITHDRAWN · sponsor: **Tiziana Life Sciences LTD**

## Conditions studied

- Covid19
- COVID-19 Lower Respiratory Infection
- COVID-19 Respiratory Infection

## Interventions

- **DRUG:** Foralumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04983446
- **Lead sponsor:** Tiziana Life Sciences LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-30
- **Primary completion:** 2022-10-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to business reasons
- **Last updated:** 2022-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04983446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04983446, "In-patient COVID-19 Study of Intranasal Foralumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04983446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*